Proposal for a new nomenclature of disease-modifying antirheumatic drugs

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 3-5

  Smolen, Josef S ^a,b   Van Der Heijde, Désirée ^c   MacHold, Klaus P ^a   Aletaha, Daniel ^a   Landewé, Robert ^d,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital Vienna   (Austria)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e Sittard Geleen Heerlen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIMALARIAL AGENT; APREMILAST; BARICITINIB; CERTOLIZUMAB PEGOL; CLAZAKIZUMAB; DIHYDROOROTATE DEHYDROGENASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOSTAMATINIB; GOLD SALT; GOLIMUMAB; HYDROXYCHLOROQUINE; IBRUTINIB; IMATINIB; INFLIXIMAB; IXEKIZUMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; SARILUMAB; SECUKINUMAB; SIRUKUMAB; TOCILIZUMAB; TOFACITINIB;

ACUTE PHASE RESPONSE; BLOOD LEVEL; CLINICAL EFFECTIVENESS; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HUMAN; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NOMENCLATURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

DMARDS (BIOLOGIC); DMARDS (SYNTHETIC); OUTCOMES RESEARCH; RHEUMATOID ARTHRITIS; TREATMENT;

ANTIRHEUMATIC AGENTS; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY; TERMINOLOGY AS TOPIC;

EID: 84889683898     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204317     Document Type: Review

References (30)

1. Amos RS, Constable TJ, Crockson RA, et al. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J 1977;1:195-7. (Pubitemid 8018411)
2. Kirwan JR, Currey HL. Rheumatoid arthritis: disease-modifying antirheumatic drugs. Clin Rheum Dis 1983;9:581-99. (Pubitemid 14241812)
3. Wright V, Amos R. Do drugs change the course of rheumatoid arthritis? Br Med J 1980;280:964-6. (Pubitemid 10071873)
4. Owen SG, Friesen WT, Roberts MS, et al. Functional capacity and treatment data from a community based study of patients with rheumatoid arthritis. Ann Rheum Dis 1986;45:293-303. (Pubitemid 16118762)
5. Greene S, Watanabe K, Braatz-Trulson J, et al. Inhibition of dihydrorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995;50:861-7.
6. Gross D, Enderlin M, Fehr K. [Immunosuppresive therapy of progredient chronic polyarthritis using antimetabolites and cytostatics]. Schweiz Med Wochenschr 1967;97:1301-10.
7. Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983;75(6A):69-73. (Pubitemid 14183623)
8. Haydu GG. Rheumatoid arthritis therapy; a rationale and the use of chloroquine diphosphate. Am J Med Sci 1953;225:71-5.
9. Freedman A, Steinberg VL. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis 1960;19:243-50.
10. Scherbel AL, Schuchter SL, Harrison JW. Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthritis. Cleve Clin Q 1957;24:98-104.
11. Svartz N. A. Therpeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparations. Acta Med Scand 1942;110:577-98.
12. Forestier J. La Chrysotherapie dans les Rhumatismes Chroniques. Bull Mem Soc Méd Hop Paris 1929;44:323-9.
13. Forestier J. The treatment of rheumatoid arthritis with gold salts injections. The Lancet 1932;219:441-4.
14. Svartz N. Salazyopyrin, a new sulfanilamide preparation. Acta Medica Scandinavica 1942;110:557-90.
15. Svartz N. The treatment of rheumatic polyarthritis with acid azo compounds. Rheumatism 1948;4:180-5.
16. Hughes JP, Rees S, Kalindjian SB, et al. Principles of early drug discovery. Br J Pharmacol 2011;162:1239-49.
17. US Food and Drug Administration. FDA approves Xeljanz for rheumatoid arthritis. 2012. http://wwwfdagov/NewsEvents/Newsroom/PressAnnouncements/ ucm327152htm
18. European Medicines Agency-CHMP. Summary of Opinion (Infliximab biosimilar). 2013. http:www.ema.europa.eu/docs/en-GB/document-library/Summary- of- opinion-Initial-authorisation/human/002576/WC500144832.pdf, editors.
19. Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-8.
20. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
21. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29:310-12.
22. Pesu M, Candotti F, Husa M, et al. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005;203:127-42. (Pubitemid 40179698)
23. Lee EB, Fleischmann RM, Hall S, et al. Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Nave Patients with Rheumatoid Arthritis. Arthritis Rheum 2012;64(Suppl):S1049.
24. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
25. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61. (Pubitemid 23219293)
26. Jespers LS, Roberts A, Mahler SM, et al. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y) 1994;12:899-903.
27. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7. (Pubitemid 30036380)
28. Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132-42. (Pubitemid 351986189)
29. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88. (Pubitemid 37361728)
30. Kelly V, Genovese M. Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology (Oxford) 2013;52:1155-62.